Clinical trials: Immune Checkpoint Inhibitor-Induced Dermatitis
Genito-Urinary Neoplasm
Microbial Diversity Between Inflamed and Non-inflamed Skin of Patients With Immune Checkpoint Inhibitor-Induced Dermatitis
This study determines microbial diversity between inflamed and non-inflamed skin of patients with immune checkpoint inhibitor-induced dermatitis. Skin has millions of bacteria.
- Trial name
- NCT04812197
- Testing
- Biospecimen Collection(Punch Biopsy)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- City of Hope Medical Center
HCC - Hepatocellular Carcinoma, Immunotherapy
Evaluation of Efficacy and Safety of Immune Check Point Inhibitors in Hepatocellular Carcinoma Patients in Ain Shams University Hospitals
This study aims to evaluate the response to immunotherapy in HCC, assess the toxicity profile and measure overall survival within the study period.
- Conditions
- HCC - Hepatocellular Carcinoma, Immunotherapy, Immune Checkpoint Therapy, Immune Checkpoint Inhibitor-Induced Dermatitis
- Trial name
- NCT07088081
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
Immune Checkpoint Inhibitor-Induced Dermatitis, Stevens-Johnson Syndrome, Drug-Induced
SJS/TEN or Other Cutaneous Adverse Eevents Induced by Immune Checkpoint Inhibitors (ICIs) vs. Non-ICIs
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) is a severe adverse drug reaction, characterized by extensive skin detachment.
- Conditions
- Immune Checkpoint Inhibitor-Induced Dermatitis, Stevens-Johnson Syndrome, Drug-Induced, Toxic Epidermal Necrolysis Due to Drug
- Trial name
- NCT06522048
- Testing
- Observational studies do not require intervention
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Chao Ji
Immune Checkpoint Inhibitor-Induced Dermatitis
JAK Inhibitors for Solid Malignant Tumor Patients With Refractory Immune Checkpoint Inhibitors-related Dermatitis
Currently, the principal strategy for immune checkpoint inhibitors (ICI)-related dermatitis include systemic use of corticosteroids, which can impair the efficacy of preceding ICIs treatment.
- Trial name
- NCT07530224
- Testing
- treated with JAK inhibitors orally for 28 days
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shixiu Wu